Chikungunya Arthritis Set to Challenge Rheumatoid Care

Chikungunya Arthritis Set to Challenge Rheumatoid Care

Publication date: Dec 11, 2025

Between 5% and 20% of individuals with chikungunya infection develop chronic arthritis that is indistinguishable from rheumatoid arthritis (RA). The autoantibody pattern, such as that of anti-cyclic citrullinated peptide antibodies, is usually less pronounced than that in classic RA, although overlap can occur in some individuals. Even the characteristic autoantibodies of the disease are positive in these patients. In August 2025, the Pan American Health Organization issued an epidemiological alert for outbreaks in Bolivia, Brazil, and Paraguay, citing 212,029 suspected cases and 110 deaths across 14 countries. Babini declared receiving honoraria, grants, and consulting fees from AbbVie, GlaxoSmithKline, Janssen, Pfizer, Boehringer Ingelheim, and Bristol Myers Squibb. Amaral declared having no relevant conflicts of interest. This story was translated from Medscapes Spanish edition.

Concepts Keywords
Arthritis Amaral
Bolivia Arthritis
Medscapes Chikungunya
Viral Chronic
Individuals
Infection
Inflammatory
Joint
Ra
Rheumatoid
Rheumatology
Said
Similar
Symptoms
Viral

Semantics

Type Source Name
drug DRUGBANK Natural alpha interferon
disease MESH chikungunya fever
disease MESH joint pain
pathway REACTOME Infectious disease
disease MESH Infectious Disease
disease MESH reactive arthritis
disease MESH dengue
disease MESH inflammation
disease MESH pain
disease MESH Mota
pathway KEGG Rheumatoid arthritis
disease MESH rheumatoid arthritis
disease MESH infection
disease MESH Arthritis
disease MESH inflammatory rheumatism
disease MESH fever
disease MESH viral infections
disease MESH fatigue
disease MESH face
disease MESH autoimmune disease
drug DRUGBANK Mesenchymal Stem Cells
pathway KEGG Viral replication

(Visited 5 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *